Related Experiment Video
Updated: Feb 3, 2026
04:43
Detection of Lung Tumor Progression in Mice by Ultrasound Imaging
Published on: February 27, 2020
7.3K
TdIF1: a putative oncogene in NSCLC tumor progression
Yujuan Zhang1,2,3, Zhigang Wang1,2, Yanqing Huang1,2
11Institute of Immunotherapy and College of Basic Medicine of Nanchang University, and Jiangxi Academy of Medical Sciences, Nanchang, China.
Signal Transduction and Targeted Therapy
|October 23, 2018
Summary
TdT-interacting factor 1 (TdIF1) promotes non-small cell lung cancer (NSCLC) growth. High TdIF1 expression correlates with poor prognosis, and its silencing reduces tumor development, suggesting TdIF1 as a therapeutic target.
Area of Science:
- Molecular Biology
- Oncology
- Cancer Research
Background:
- TdT-interacting factor 1 (TdIF1) is a DNA/protein-binding factor with an unknown role in cancer.
- TdIF1 has not been previously identified as aberrant in any cancer type.
Purpose of the Study:
- To investigate the role of TdIF1 in non-small cell lung cancer (NSCLC) development.
- To determine if TdIF1 expression correlates with patient prognosis.
Main Methods:
- Analysis of TdIF1 expression in clinical NSCLC samples and cell lines.
- shRNA-mediated gene silencing of TdIF1 in NSCLC cells (A549).
- Assessment of proliferation, colony formation, and tumor growth in mouse xenograft models.
- In silico pathway analysis (p53, HDAC1/2) followed by transcriptomic and proteomic validation.
Main Results:
- TdIF1 is abundantly expressed in clinical NSCLC and associated with poor prognosis.
- TdIF1 is highly expressed in NSCLC cell lines compared to normal lung cells.
- TdIF1 silencing suppressed NSCLC cell proliferation, colony formation, and reduced tumor size in vivo.
- TdIF1 downregulation modulated p53 and HDAC1/2 pathways and affected cell cycle regulators like CDKN1A/p21.
Conclusions:
- TdIF1 acts as a tumor-promoting factor in NSCLC.
- TdIF1 is a potential therapeutic target for NSCLC treatment.
Related Concept Videos
02:07Tumor Progression
7.4K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.4K
01:33Cancer-Critical Genes I: Proto-oncogenes
11.5K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
11.5K
03:03mTOR Signaling and Cancer Progression
4.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.8K
01:27Tumor Immunotherapy
1.9K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.9K
02:17The Tumor Microenvironment
7.8K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.8K
02:40Cancer Stem Cells and Tumor Maintenance
6.0K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
6.0K